Phase 1/2 Study of Vactosertib (TEW-7197) Monotherapy in Patients With Low or Intermediate Myelodysplastic Syndromes
Phase of Trial: Phase I/II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs TEW 7197 (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors MedPacto
- 10 Jan 2018 Status changed from not yet recruiting to recruiting.
- 11 Nov 2017 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019.
- 11 Nov 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.